Estudo de Viabilidade do Sistema de Oclusão e Reversão Plan A
Estudo Clínico Intervencional, Prospetivo, Multicêntrico, de Braço Único e Aberto, que Investiga a Segurança e Eficácia do Sistema Contraceptivo Masculino Plan A.
Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens. 40 men (all sites) will be enrolled and treated with Plan A occlusion (Vasalgel®) using DLAD (Delivery Lumen Access Device). The study will enroll into two groups. Group 1 will include 30 subjects that will be followed for up for a maximum of 6 months post occlusion procedure, or until they achieve azoospermia at which point they will be offered a vasectomy procedure. Group 2 will recruit ten subjects who will be followed for up for a maximum of 6 months post occlusion procedure, or until they achieve azoospermia at which point they will have the reversal procedure using the Plan A RD (Reversal Device). This group will be followed for up to another 3 months maximum, or until baseline semen levels are achieved at which point they will be offered a vasectomy procedure. Ten men reaching azoospermia after their occlusion procedure will be allocated to Group 2 and will go on to have the reversal procedure.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Darlene Walley R Chief Executive Officer, PhD
- Número de telefone: 1-415-407-5229
- E-mail: darlene.walley@nextlifesciences.org
Locais de estudo
-
-
Victoria
-
Maribyrnong, Victoria, Austrália, 3032
- Recrutamento
- Western Urology
-
Contato:
- Homi Zargar, MD
- Número de telefone: +1 61 300 927 427
- E-mail: pa@homizargar.com.au
-
St Kilda, Victoria, Austrália, 3182
- Recrutamento
- Dr. Snip
-
Contato:
- Sarah Demediuk, MD
- Número de telefone: 1300 377 647
- E-mail: sarah@drsnip.au
-
-
-
-
Ontario
-
Hawkesbury, Ontario, Canadá, K6A 1A8
- Ainda não está recrutando
- Clinique de Vasectomie
-
Contato:
- Jean Philippe-Bercier, MD
- Número de telefone: 613-762-0997
- E-mail: jeanphilippebercier@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male subject who is seeking and suitable to undergo a vasectomy as a long-term form of contraception
- Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form (ICF) for this study prior to initiation of any screening or study specific procedures
- 25 to 65 years of age at the time of consent
- Body Mass Index (BMI) <31 kg/m2
- Good health for undergoing a vasectomy as confirmed by medical history, physical examination and clinical laboratory tests of blood and urine at the time of screening
- Normal semen analysis defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (6th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart
- In the opinion of the Investigator, subject is suitable to undergo a vasectomy as a form of long-term contraception
- Agreement to use an effective method of contraception during the entire clinical trial until the planned vasectomy
- Lives in close proximity to the trial site to enable provision of fresh semen samples unless the subject agrees to provide semen samples at the trial site or laboratory
Exclusion Criteria:
- (On exam, has any of the following); one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study.
- Prior testicular surgery, testicular injury or prior vasectomy with vasovasostomy (vasectomy reversal)
- Recurrent pain with ejaculations
- Has known allergic reaction to sulfur-containing products or has had a prior severe allergic response to injectable or implantable devices
- Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection
- History of prostatitis or benign prostatic hypertrophy requiring treatment
- Has undergone prior chemotherapy
- Has known current coagulopathy or other bleeding disorders
- Currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)
- Subjects with cystic fibrosis
- Subjects with a history of inguinal hernia repair
- Vulnerable subjects (e.g., subjects with cognitive challenges, incarcerated, etc.)
- Currently participating in another study involving an investigational device or drug (or has participated in a study within the last 30 days prior to screening).
- Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities
- In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study
- Has any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group 1: Occlusion Procedure
This will be Group 1. Group1 will have the occlusion procedure but will not have the reversal procedure. |
The occlusion system comprised of the Delivery Lumen Access Device and Vasalgel. |
|
Experimental: Group 2: Reversal Procedure
This will be Group 2. Group 2 will have both the occlusion and reversal procedure. |
The occlusion system comprised of the Delivery Lumen Access Device and Vasalgel. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Study subjects achieving azoospermia
Prazo: Starting at the 30 day follow-up visit
|
Total number of subjects (N=40) achieving azoospermia |
Starting at the 30 day follow-up visit
|
|
Study subjects that return to baseline semen levels
Prazo: Correlating to Outcome 1, that follow-up timepoint at which azoospermia is reached starting at the 30 day follow-up
|
Total number of subjects (N=10) that return to baseline semen levels after reversal |
Correlating to Outcome 1, that follow-up timepoint at which azoospermia is reached starting at the 30 day follow-up
|
|
Adverse Events
Prazo: From the first subjects screening visit through the last subjects 14 Day phone follow up visit.
|
Rate and severity of adverse events. |
From the first subjects screening visit through the last subjects 14 Day phone follow up visit.
|
|
Subject Comfort
Prazo: From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Subject Comfort Assessment Scale Post Occlusion and Reversal |
From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
|
Histology
Prazo: From the first subjects occlusion visit until the last subjects vasectomy, approximately 9 months
|
Excised portion of the vas deferens will be prepared with formalin for histological evaluation |
From the first subjects occlusion visit until the last subjects vasectomy, approximately 9 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Subject Satisfaction/Comfort Assessment
Prazo: From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Patient satisfaction questions along with NRS pain scale are being utilized to determine the comfort of the patient |
From the first subjects occlusion visit until the last subjects 14 Day phone follow up visit.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Homi Zargar, MD, Western Urology
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- CIP102
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .